Beam Therapeutics (BEAM) EBITDA Yield: History & Chart

Beam Therapeutics Inc.(BEAM)

Biotechnology · Cambridge, MA

$24.50+0.11 (+0.45%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Beam Therapeutics Inc.

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Cambridge, MA

540 employees

www.beamtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Evans

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Beam Therapeutics Inc. (BEAM)	$2.52B	N/A	N/A	N/A	N/A
TransMedics Group, Inc. (TMDX)vs ›	$2.76B	3.74%	2.98%	2.17%	2.17%
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.16B	N/A	N/A	N/A	N/A
DENTSPLY SIRONA Inc. (XRAY)vs ›	$1.74B	22.42%	14.95%	6.63%	7.26%
Intellia Therapeutics, Inc. (NTLA)vs ›	$1.71B	N/A	N/A	N/A	N/A
Teladoc Health, Inc. (TDOC)vs ›	$1.00B	8.03%	4.46%	2.35%	2.35%
NeoGenomics, Inc. (NEO)vs ›	$474.59M	N/A	1.44%	5.28%	7.05%
NRC Health (NRC)vs ›	$458.62M	4.28%	6.59%	7.36%	6.54%
Shoulder Innovations, Inc. (SI)vs ›	$394.23M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$41.86M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Beam Therapeutics Inc. (BEAM)

$2.52B

N/A

TransMedics Group, Inc. (TMDX)vs ›

$2.76B

3.74%

2.98%

2.17%

Recursion Pharmaceuticals, Inc. (RXRX)vs ›

$2.16B

N/A

DENTSPLY SIRONA Inc. (XRAY)vs ›

$1.74B

22.42%

14.95%

6.63%

7.26%

Intellia Therapeutics, Inc. (NTLA)vs ›

$1.71B

N/A

Teladoc Health, Inc. (TDOC)vs ›

$1.00B

8.03%

4.46%

2.35%

NeoGenomics, Inc. (NEO)vs ›

$474.59M

N/A

1.44%

5.28%

7.05%

NRC Health (NRC)vs ›

$458.62M

4.28%

6.59%

7.36%

6.54%

Shoulder Innovations, Inc. (SI)vs ›

$394.23M

N/A

PDS Biotechnology Corporation (PDSB)vs ›

$41.86M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

BEAM EBITDA Yield Metrics

BEAM Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics